Fulcrum Therapeutics, Inc. (FULC) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Fulcrum Therapeutics, Inc. (FULC) posted $0 in revenue for fiscal 2025 (down 100.0% year over year), with a net loss of $74.88M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. has grown revenue from — to $0 over the last 8 fiscal years. The most recent year was down 100%.
It clears 1 of 5 deterministic health checks. The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Fulcrum Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Fulcrum Therapeutics, Inc.? Check it against the filing
Open the full tool →Paste a headline number you saw about FULC — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Fulcrum Therapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $8.82M | $19.16M | $6.34M | $2.81M | $80.00M | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-32.59M | $-82.68M | $-70.82M | $-80.85M | $-109.87M | $-97.33M | $-9.72M | $-74.88M |
| Net margin | — | — | -802.7% | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
Source: Fulcrum Therapeutics, Inc. SEC filings (10-K).
Fulcrum Therapeutics, Inc. financial health: 1 of 5 checks passed
- ✗Profitable every year (last 5)
- ✓More cash than total debt (cash 352.3M vs debt 0M)
- ✗Positive operating cash flow (last 5 yrs)
- ✗Free cash flow positive (latest yr) (-60.4M)
- ✗Share count falling over 5 yrs (buybacks) (27.9M → 66.6M shares)
Checks computed deterministically from filed annual statements — no AI judgement.
Fulcrum Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 63.9% over 4 years (40.6M → 66.6M) — existing holders' stakes are being diluted.
Explore 8 years of Fulcrum Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track FULC in your portfolio →
Fulcrum Therapeutics, Inc. financial history
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc. — frequently asked questions
What is Fulcrum Therapeutics, Inc.'s revenue?
Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Fulcrum Therapeutics, Inc. profitable?
No — FULC reported a net loss of $-74.88M in fiscal 2025.
What is Fulcrum Therapeutics, Inc.'s market cap?
Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of about $232.22M, based on the latest data in our nightly-refreshed cache.
When does Fulcrum Therapeutics, Inc.'s fiscal year end?
FULC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Fulcrum Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.